Treatment of immunoglobulin A nephropathy

Annales de Medecine Interne

Volumn 150, Issue 2, 1999, Pages 127-136

  Schiele, Jörg ^a   Nowack, Rainer ^a   Julian, Bruce A ^b   Van Der Woude, Fokko Johannes ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b University of Alabama at Birmingham   (United States)

Author keywords

Berger's disease; Drug therapy; Glomerulonephritis; IgA nephritis; IgA nephropathy; Immunoglobulin A nephropathy; Recurrent disease; Relapse; Therapy; Transplantation

Indexed keywords

ALPHA TOCOPHEROL; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FISH OIL; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEGA 3 FATTY ACID; PLACEBO; WARFARIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFECT; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY TRANSPLANTATION; META ANALYSIS; NEPHROTIC SYNDROME; PROTEIN INTAKE; PROTEINURIA; RECURRENT DISEASE; REVIEW; TREATMENT PLANNING;

EID: 0033062914     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. HOTTA O, TAGUMA Y, KUROSAWA K, SUDO K, SUZUKI K, Horigome I. Early intensive therapy for clinical remission of active IgA nephropathy: a three-year follow-up study. Jap J Nephrol 1993; 35: 967-73.
2. DUQUE N, GOMEZ-GUERRERO C, EGIDO J. Interaction of IgA with Fc alpha receptors of human mesangial cells activates transcription factor nuclear factor-kappa B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. J Immunol 1997; 759: 3474-82.
3. MORRISSEY JJ, KLAHR S. Enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. Kidney Int 1997; 52: 926-33.
4. REKOLA S, BERGSTRAND A, BUCHT H. Deterioration rate in hypertensive IgA nephropathy: comparison of ACE inhibitor and beta-blocking agents. Nephron 1991; 57: 57-60.
5. CATTRAN D, GREENWOOD C, RITCHIE S: Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994; 23: 247-54.
6. MASCHIO G, CAGNOLI L, SLARONI F, FUSAROLI M, RUGIU C, SANNA G, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomised, placebo-controlled trial. Nephrol Dial Transplant 1994; 9: 265-9.
7. BANNISTER KM, WEAVER A, CLARKSON AR, WOODROFFE AJ. Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 1995; 111: 184-93.
8. GIATRAS I, LAU J and LEVEY AS, for the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: A meta-analysis of randomized trials. Ann Intern Med 1997; 127: 337-45.
9. SCHUNKERT H. Polymorphism of the angiotensin-converting enzyme gene and cardiovascular disease. J Mol Med 1997; 75: 867-75.
10. HARDEN PN, GEDDES C, ROWE PA, MCILROY JH, BOULTON-JONES M, RODGER RS, JUNOR BJ, BRIGGS JD, CONNELL JM, JARDINE AG. Polymorphism in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 1995; 345 (8964): 1540-2.
11. HUNLEY TE, JULIAN BA, PHILLIPS JA 3RD, SUMMAR ML, YOSHIDA H, HORN RG, BROWN NJ, FOGO A, ICHIKAWA I, KON V. Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996; 49: 571-7.
12. YORIOKA T, SUEHIRO T, YASUOKA N, HASHIMOTO K, KAWADA M. Polymorphism of the angiotensin converting enzyme gene and clinical aspects of IgA nephropathy. Clin Nephrol 1995; 44: 80-5.
13. YOSHIDA H, MITARAI T, KAWAMURA T, KITAJIMA T, MIYAZAKI Y, NAGASAWA R, KAWAGUCHI Y, KUBO H, ICHIKAWA I, SAKAI O. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy J Clin Invest 1995; 96: 2162-9.
14. FUKUSHIMA T, NOMURA S, KAWAI S, OSAWA G. ACE genotype and progression of IgA nephropathy. Lancet 1995 26; 346 (8974): 571.
15. SCHMIDT S, STIER E, HARTUNG R, STEIN G, BAHNISCH J, WOODROFFE AJ, et al. No association of converting enzyme insertion/deletion polymorphism with immunoglobulin A glomerulonephritis. Am J Kidney Dis 1995; 26: 727-31.
16. VAN ESSEN GG, RENSMA PL, DE ZEEUW D, SLUITER WJ, SCHEFFER H, APPERLOO AJ, DE JONG PE. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996; 347 (8994): 94-5.
17. SCHMIDT S, RITZ E. Genetic factors in IgA nephropathy. Ann Med Interne (Paris) 1999; 150: 86-90.
18. GANSEVOORT RT, DE ZEEUW D. SHAHINFAR S, REDFIELD A, DE JONG PE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens Suppl 1994; 12: S37-S42.
19. PITT B, SEGAL R, MARTINEZ FA, MEURERS G, COWLEY AJ, THOMAS I, DEEDWANIA PC, NEY DB, CHANG PI, ELITE Study Investigators: Randomized trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1998; 349: 747-52.
20. SCHENA FP, MONTENEGRO M, SCIVITTARO V. Meta-analysis of randomised controlled trials in patients with IgA nephropathy. Nephrol Dial Transplant Suppl. 1, 1990; 5: 47-52.
21. LAI KN, LAI FM, Ho CP, CHAN KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986; 26: 174-80.
22. JULIAN BA, BARKER C. Alternate-day prednisone therapy in IgA nephropathy. Contrib Nephrol 1993; 104: 198-206.
23. FEEHALLY J. Immunoglobulin A nephropathy: fish oils and beyond. Curr Opin Nephrol Hypertens. 1996; 5: 442-6.
24. GOUMENOS D, AHUJA M, SHORTLAND JR, BROWN CB. Can immunosuppressive drugs slow the progression of IgA nephropathy? Nephrol Dial Transplant 1995; 10: 1173-81.
25. KOBAYASHI Y, HIKI Y, FUJII K, KUROKAWA A, TATENO S. Moderately proteinuric IgA nephropathy: prognostic prediction of individual clinical courses and steroid therapy in progressive cases. Nephron 1989; 53: 250-6.
26. KOBAYASHI Y, HIKI Y, KOKUBO T, HORII A, TATENO S. Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron 1996; 72: 237-42.
27. th International IgA Nephropathy Symposium, 1998, Abstract book, page 45.
28. HOGG RJ. A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with IgA nephropathy. Am J Kidney Dis 1995; 26: 792-6.
29. WOO KT, EDMONDSON RPS, YAP HK, WU AYT, CHIANG GSC, LEE EJC, PWEE HS, LIM CH. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clin Nephrol 1989; 27: 58-64.
30. WALKER RG, YU SH, OWEN JE, KINCAID-SMITH P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two year prospective trial. Clin Nephrol 1990; 34: 103-7.
31. LEE GSL, WOO KT, LIM CH. Controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephritis with renal impairment, Clin Nephrol 1989; 311: 276.
32. FAEDDA R, PIRISI M, SATTA A, BOSINCU L, BARTOLI E. Immunosuppressive treatment of Berger's disease. Clin Pharmacol Ther 1996; 60: 561-7.
33. BALLARDIE FW, ROBERTS ISD. A controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. Nephrol Dial Transplant 1996; 11: 1684.
34. LAI KN, LAI FM-M, LI PKT, VALLENCE-OWEN J. Cyclosporin treatment of IgA nephropathy: a short term controlled trial. Br Med J 1987; 295: 1165-8.
35. CHABOVA V, TESAR V, ZABKA J, RYCHLÍK I, MERTA M, JIRSA JR. M, STEJSKALOVÁ A. Long term treatment of IgA nephropathy with cyclosporin A - a preliminary report. Nephrol Dial Transplant 1997; 12: 2206-7.
36. ODUM J, PEH CA, CLARKSON AR, et al. Recurrent mesangial IgA nephritis following renal transplantation. Nephrol Dial Transplant 1994; 9: 309-12.
37. SCHWARZ A, KRAUSE PH, OFFERMANN G, KELLER F. Recurrent and de novo renal disease after kidney transplantation with or without cyclosporine A. Am J Kidney Dis 1991; 17:524-31.
38. NOWACK R, BIRCK R, VAN DER WOUDE FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349: 774.
39. BRIGGS WA, CHOI MJ, SCHEEL PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998; 31: 213-7.
40. JULIAN BA, SAID M, BARKER CV. Allograft loss in IgA nephropathy (abstract). J Am Soc Nephrol 1998; 9: 91 A.
41. ROSTOKER G, DESVAUX-BELGHITI D, PILATTE Y, PETIT-PHAR M, PHILIPPON C, DEFORCES L, et al. High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schönlein purpura. Ann Intern Med 1994; 120: 476-84.
42. ROSTOCKER G, DESVAUX-BELGHITI D, PILATTE Y, PETIT-PHAR M, PHILIPPON C, DEFORCES L, et al. Immunomodulation with low-dose immunoglobulins for moderate IgA nephropathy and Henoch-Schönlein purpura. Preliminary results of a prospective uncontrolled trial. Nephron 1995; 69: 327-34.
43. HAMAZAKI T, TATENO S, SHISHIDO H. Eicosapentaenoic acid and IgA nephropathy. Lancet 1984; I (8384); 1017-8.
44. BENNETT WM, WALKER RG, KINCAID-SMITH P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA: a two-year prospective trial. Clin Nephrol 1989; 31: 128-31.
45. CHENG IK, CHAN PC, CHAN MK. The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulonephritis. Nephrol Dial Transplant 1990; 5: 241-6.
46. PETTERSSON EE, REKOLA S, BERGLUND L, SUNDQVIST KG, ANGELIN B, DICZFALUSY U, BJORKHEM I, BERGSTROM J. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study. Clin Nephrol 1994; 41: 183-90.
47. DONADIO JV JR, BERGSTRALH EJ, OFFORD KP, SPENCER DC, HOLLEY KE. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994; 331: 1194-9.
48. DONADIO JV JR, GRANDE JP, BERGSTRALH EJ, DART RA, LARSON TS. The long-term outcome of patients with IgA nephropathy treated with fish oil in a placebo-controlled, randomized clinical trial (abstract). J Am Soc Nephrol 1998; 9: 145 A.
49. YPERSELE DE STRIHOU C. Fish oil for IgA nephropathy. N Engl J Med 1994; 331: 1227-8.
50. HOLMAN RT, JOHNSON SB, BIBUS D, SPENCER DC, DONADIO JV Jr. Essential fatty acid deficiency profiles in idiopathic IgA nephropathy. Am J Nephrol 1994; 23: 648-54.
51. DILLON JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 1997; 8 (11): 1739-44.
52. CLARKSON AR, WOODROFFE AJ, BANNISTER KM, ODUM J. Therapy in IgA nephropathy. Contrib Nephrol 1993; 104: 189-97.
53. BLUM DJ, NEEL HB. Current thinking on tonsillectomy and adenoidectomy. Compr Ther 1983; 9: 48-56.
54. LAGRUE G, SADRENX T, LAURENT J, HIRBEE G. Is there a treatment of mesangial IgA glomerulonephritis? Clin Nephrol 1980; 14: 161.
55. BENE MC, HURAULT DE LIGNY B, KESSLER M, FOLIGUET B, FAURE GC. Tonsils in IgA nephropathy. Contrib Nephrol 1993; 104: 153-61.
56. IINO et al. Chronic tonsillitis and IgA nephropathy. Clinical study of patients with and without tonsillectomy. Acta Otolaryngol 1993; 508: 29-35
57. BARTA J, KOVACS T, FAZEKAS A, JEGES S, NAGY G, NAGY J. Does tonsillectomy cause any change in long-term course of IgA nephropathy? Orv Hetil 1996; 137: 2903-6.
58. TEVLIN MT, WALL BM, COOKE CR. Reversible renal failure due to IgA nephropathy associated with osteomyelitis. Am J Kidney Dis 1992; 20: 185-8.
59. EGIDO J, RIVERA F, SANCHO J, BARAT A, HERNANDO L. Phenytoin in IgA nephropathy: a long-term controlled trial. Nephron 1984; 38: 30-9.
60. CLARKSON AR, SEYMOUR AE, WOODROFFE AJ, MCKENZIE PE, CHAN YL, WOOTON AM. Controlled trial of phenytoin therapy in IgA nephropathy. Clin Nephrol 1980; 13: 215-8.
61. ADAMKOVA V, MATOUSOVIC K, PRAT V. Vliv difenylhydantoinu na IgA nefropatii. (The effect of diphenylhydantoin on IgA nephropathy) Casopis Lekaru Ceskych 1989; 128: 524-6
62. COPPO R, BASOLO B, ROCCATELLO D, et al. Plasma exchange in progressive primary IgA nephropathy. In J Artif Organs 1985; 2: 55-8.
63. NICHOLLS K, BECKER G, WALKER R, WRIGHT C, KINCAID-SMITH P. Plasma exchange in progressive IgA nephropathy. J Clin Apheresis 1990; 5: 128-32.
64. FERRI C, PUCCINI R, LONGOBARDO G, PALEOLOGO G, MIGLIORINI P, MORICONI L, PASERO G, CIONI L. Low-antigen-content diet in the treatment of patients with IgA nephropathy. Nephrol Dial Transplant 1993; 8: 1193-8.
65. PEDRINI MT, ANDREW SL, LAU J, CHALMERS TC, WANG PH. The effect of dietary protein restriction on the progression of diabetic and non-diabetic renal diseases: a meta-analysis. Am Intern Med 1996; 124: 627-32
66. FRASCÀ GM, MARTELLO M, SESTIGIANI E, CANOVA C, VANGELISTA A, BONOMINI V. Effects of defibrotide treatment in patients with IgA nephropathy and reduced renal function. Nephrol Dial Transplant. 1996; 11: 392-3.
67. MIURA M, ENDOH M, NOMOTO Y, SAKAI H. Long-term effect of urokinase therapy in IgA nephropathy. Clin Nephrol 1989; 32: 209-16.
68. CHAN W, KRIEG RJ JR, NORKUS EP, CHAN JC. Alpha-tocopherol reduces proteinuria, oxidative stress, and expression of transforming growth factor beta 1 in IgA nephropathy in the rat. Mol Genet Metab 1998; 63: 224-9
69. SCHEINMAN JI, TRACHTMAN H, LIN CY, LANGMAN CB, CHAN JC. IgA nephropathy: to treat or not to treat? Nephrol Dial Transplant. 1996; 11: 392-3.
70. TRACHTMAN H, CHAN JC, CHAN W, VALDERRAMA E, BRANDT R, WAKELY P, FUTTERWEIT S, MAESAKA J, MA C. Vitamin E ameliorates renal injury in an experimental model of immunoglobulin A nephropathy. Pediatr Res 1996; 40: 620-6.
71. OHMACHT C, KLIEM V, BURG M, NASHAN B, SCHLITT HJ, BRUNKHORST R, KOCH KM, FLOEGE J. Recurrent immunoglobulin A nephropathy after renal transplantation: a significant contributor to graft loss. Transplantation 1997; 64: 1493-6.